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Abstract: Gene therapy is a fundamentally novel therapeutic approach that involves introducing genetic material into tar-
get cells in order to fight or prevent disease. A number of different strategies of gene therapy are tested at experimental 
and clinical levels, including: a) replacing a mutated gene that causes disease with a healthy copy of the gene, b) inactivat-
ing a mutated gene that its improper function causes pathogenesis, c) introducing a new gene coding a therapeutic com-
pound to fight a disease, d) introducing to the target organ an enzyme converting an inactive pro-drug to its cytotoxic me-
tabolite. In gene therapy, the transcriptional machinery of the patient is used to produce the active factor that exerts the in-
tended therapeutic effect, ideally in a permanent, tissue-specific and manageable way. The liver is a major target for gene 
therapy, presenting inherited metabolic defects of single-gene etiology, but also severe multifactorial pathologies with 
limited therapeutic options such as hepatocellular carcinoma.  The initial promising results from gene therapy strategies in 
liver diseases were followed by skepticism on the actual clinical value due to specificity, efficacy, toxicity and immune 
limitations, but are recently re-evaluated due to progress in vector technology and monitoring techniques. The significant 
amount of experimental data along with the available information from clinical trials are systematically reviewed here and 
presented per pathological entity. Finally, future perspectives of gene therapy protocols in hepatology are summarized.  
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INTRODUCTION 
 Despite the immense advances in the understanding of 
the etiology of several liver pathologies at a molecular level, 
treatment responses remain poor and outcome limited, im-
posing emerging need for novel therapeutic alternatives. Ge-
netic manipulations for altering gene expression pattern in
vivo with therapeutic outcome, known as gene therapy, offer 
a fundamentally different to pharmacotherapy approach for 
inherited as well as acquired diseases. Gene therapy, one of 
the greatest achievements of biomedical science, is based on 
genetic material transfer techniques in the affected or other 
relevant tissues, in order to stop the pathogenetic process. 
Using the host’s cell protein synthetic machinery, permanent, 
tissue specific and controllable changes in gene expression 
are attempted, that aim to overcome the limitations of classi-
cal pharmacology at the level of chemical synthesis and sta-
bility of therapeutically useful substances, toxicity, even 
cost.  
 Many liver diseases such as hereditary metabolic defects, 
hepatitis, cirrhosis and primary or metastatic cancer are ame-
nable for gene therapy approaches. The pathology of liver 
offers theoretically ideal candidates for gene therapy strate-
gies: serious, life-threatening disease, often with known or of 
single-gene etiology, and limited, ineffective treatment op- 
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tions, either surgical or pharmacological. Numerous experi-
mental data have been accumulated, which argue that genetic 
strategies can be tailored to liver disorders, some of those 
seen in clinical trials underway. In most studies, the thera-
peutic nucleic acid is delivered directly or using viral vectors 
with better transfection efficiency, usually adenoviruses be-
cause they exhibit tropism for the liver. Administration can 
be via intravascular, intra-hepatic or biliary routes. In addi-
tion, due to the physiology of the tissue, gene modification 
of the hepatic parenchyma could turn it into an endogenous 
laboratory for the production of protein-drugs to treat dis-
eases that do not directly affect its function.  
 In spite of several approaches, human gene therapy in 
liver diseases is still in its infancy. The experience to apply 
protocols in clinical practice that derives from impressive 
initial results from in vitro and in vivo preclinical studies 
shows significant expected and unexpected barriers and 
poses questions about their future. The challenges associated 
with liver-directed gene therapy are efficient targeting of 
hepatocytes, stability of the vector genome, and persistent 
high level expression [1]. In this review, we present the 
knowledge acquired: what are the strategies developed, the 
technical possibilities and obstacles, and finally, what seems 
to be of therapeutic value of gene therapy in liver diseases? 
VECTORS AND TREATMENT STRATEGIES 
 A gene that is inserted directly into a cell usually does 
not function. A carrier called vector is often used to intro-
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duce a therapeutic gene into the host’s target cells. The most 
common vector is a virus that has been genetically altered to 
carry normal human DNA. Target cells such as hepatocytes 
are infected by the vector, which unloads its genetic material 
containing the therapeutic human gene into the cell genome. 
The generation of a functional protein product from the 
therapeutic gene restores the target cell or the adjunct tissue 
to a normal state. 
 Gene therapy vectors can be constructed on the basis of 
viral or non-viral molecular structures [2]. Integrating RNA-
viruses and the non-integrating DNA-viruses have been used 
as viral vectors. The first are subcategorized in a) retrovi-
ruses that deliver copies of their RNA genomes that is re-
verse transcribed to DNA and b) lentiviruses which can de-
liver large amounts of DNA into the cell and replicate in 
non-dividing cells. Non-integrating DNA-viruses are sub-
categorized in: a) Adenoviruses (Ads), with double-stranded 
DNA genomes; their drawback is respiratory, intestinal and 
eye infections in humans, b) Adeno-Associated Viruses 
(AAV) are small, single-stranded DNA viruses; their genetic 
material can be inserted at a specific site on chromosome 19, 
and currently, they are among the most frequently used viral 
vectors for gene therapy and c) Herpes simplex viruses 
(HSV) are a class of double-stranded viruses that can infect a 
particular cell type, i.e. neurons. 
 Adenovirus (Ad) based gene transfer vectors continue to 
be the platform of choice for an increasing number of clini-
cal trials worldwide. In fact, within the last years, the number 
of clinical trials that utilize Ad based vectors has increased 
dramatically, indicating growing enthusiasm for the numer-
ous positive characteristics of this gene transfer platform. 
However, for the human adenovirus serotype 5 (Ad5), the 
most frequently used vector prototype; three major limita-
tions have been identified: widespread pre-existing anti-Ad5 
immunity in humans [3, 4], an unacceptably large amount of 
damage to normal non-target tissues, which causes severe 
toxicity [5, 6], and low levels of target-specific gene delivery 
[7-9]. Several efforts have been made towards diminishing 
the immune response. These strategies include, modification 
of viral capsids [10], covalent conjugation of polyethle-
neglycol (PEG) to Adv [11-14], hydrodynamic injections 
towards local delivery of low vector doses directly into the 
liver [15], pretreatment with glucocorticoids, use of lipid 
bilayer envelopes, and preventing binding to the CAR recep-
tor by masking the adenoviral fiber knob [16-18]. Recent 
data suggest that combination of immunotherapy with che-
motherapy can overcome the inability to give multiple doses, 
resulting in the boosting of the initial vaccination of the ade-
novirus [19]. Collectively, these findings indicate modified 
Ad vector protocols better suited for gene transfer in hu-
mans. 
 In the non-viral vectors for gene delivery the transferred 
gene is in the form of a plasmid [20] that is on the surface or 
in the interior of the vector. Such vectors include liposomes 
[21], molecular conjugates [22], nanoparticles [23], naked 
DNA [24] and complex DNA [25]. In order for more effi-
cient transfection to be achieved, delivery systems, such as 
cationic lipids and cationic polymers were used [26]. In this 
case, the carrier is an artificial lipid sphere (a liposome) with  
an aqueous core carrying the therapeutic DNA, which is ca-
pable of transporting the DNA through the target’s cell 
membrane.  
 Another way of introducing therapeutic DNA into target 
cells is by chemically linking the DNA to a molecule that 
will bind to specific cell receptors where it constructs and is 
engulfed by the cell membrane and then is passed into the 
interior of the target cell. This delivery system is however 
less effective than the other options. 
 In addition, experiments with the introduction of a 47th
chromosome (an artificial, human techno-chromosome) into 
target cells are being carried out [2]. This chromosome 
would exist autonomously alongside the standard 46, without 
affecting their functions or causing any mutations. The con-
struction and the autonomy of this large vector, not only 
would make it invisible to the body’s immune system, but 
also able to carry substantial amounts of the genetic code. A 
disadvantage with this method is the difficulty in delivering 
such a large molecule into the nucleus of a target cell. 
 Another delivery method is the Sleeping Beauty Trans-
poson System (SBTS), a non-viral gene delivery vehicle 
found ubiquitously in nature. Transposon-based vectors have 
the capacity of stable genomic integration and long-lasting 
expression of transgene constructs in cells [27]. The SBTS 
consists of the SB Transposon, the SB Transposase – spe-
cific to the SB Transposon and a therapeutic gene. 
 An alternative non-viral option is RNA interference 
(RNAi), which includes a sequence-specific RNA degrada-
tion process in the cytoplasm of eukaryotic cells that is in-
duced by double-stranded RNA (dsRNA). This endogenous 
regulatory RNA silencing mechanism, which was first de-
scribed in Caenorhabditis elegans and Drosophila mela-
nogaster, also possesses many similarities with post-
transcriptional gene silencing in plants, and the process of 
quelling in Neurospora crassa [28, 29]. RNAi and related 
RNA silencing mechanisms are supposed to act as a natural 
defense against incoming viruses and the expression of 
transposable elements [30]. Moreover, with the antiviral 
function of RNAi, there is evidence that RNAi plays an im-
portant role in regulating cellular gene expression. The use 
of RNAi in gene therapy is to disrupt the translation of the 
faulty mRNA, which is induced by the signal to the signal, to 
cleave specific unique sequences in the mRNA transcript of 
the faulty gene. An alternative for gene silencing is the use 
of specific oligonucleotides antisense to the target gene [2]. 
In order to overcome the low efficiency of editing genes at 
their natural location, zinc-finger nucleases (ZFNs) have 
been constructed which augment this efficacy by making a 
break in the target site. The ability to modify the DNA-
binding specificity of the ZFNs makes them applicable to 
targeting essentially any desired gene [31]. Despite the fact 
that the ZFN field is still in its early stages, the potential of 
ZFNs for gene targeting is indeed successfully used, includ-
ing mostly animal and human genes [32]. There is some 
danger, however, that the use of additional fingers will lead 
to cleavage more sequences that are off target, since a subset 
may be sufficient to direct binding [31]. Pruett-Miller et al., 
[33] for example, has shown greater cytotoxicity with a par-
ticular pair of 4-finger ZFNs. 
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 Finally, another approach is gene-directed enzyme-
prodrug therapy (GDEPT) or suicide gene therapy, which is 
comprised of three components; the pro-drug to be activated, 
the enzyme (usually nonhuman) used for activation, and the 
delivery system for the corresponding gene [34]. Pro-drugs 
can be considered as a combination of two major domains; a 
“trigger” unit that is the substrate for the activating enzyme, 
and an “effector” unit that is activated or released by this 
metabolic process, sometimes joined by a definable linker 
[35]. The most prominent GDEPT therapy has been the use 
of the herpes simplex type-1 thymidine kinase enzyme 
(HSV-Tk) in conjunction with a variety of guanosine based 
pro-drugs, compounds originally developed as antiviral (anti-
herpes) agents [36-38]. Ganciclovir (GCV; 1a) is the most 
widely used pro-drug for HSV-Tk, and is well known as an 
antiviral agent [38]. The cytosine deaminase gene is the next 
most widely studied for GDEPT. 
 Tested approaches for DNA delivery in liver diseases 
include nanoparticles, DNA plasmids with cationic lipids, 
liposomes and others. AAV vectors offer a more promising 
alternative, as they are capable of maintaining high levels of 
hepatic transgene expression for prolonged periods of time, 
particularly when regulated by tissue-specific enhancers and 
promoters [39-41]. In addition, significantly higher hepatic 
transduction efficiencies by administrating relatively low 
viral dosages has been succeeded, since the discoveries of 
novel AAV serotypes, such as AAV8 and 9 [42]. Compared 
to other viral-based gene therapy vectors, AAV vectors have 
a favorable biosafety profile, because they are less inflamma-
tory and the wild-type virus is nonpathogenic as well as rep-
lication-deficient [43]. AAV8 has been shown to be the most 
efficient vector for liver-directed gene transfer and is cur-
rently being evaluated in a clinical trial for treating hemo-
philia B [44, 45] (Table 1).  
SEARCH STRATEGY 
 We performed an electronic article search through Pub-
Med, Google Scholar, Medscape and Scopus databases, us-
ing combinations of the following keywords: Gene Therapy, 
Lysosomal storage disease, Acute intermittent porphyria, 
Ornithine transcarbamylase deficiency, (1)-antitrypsin defi-
ciency, acute liver failure, PompeDisease, Tyrosinemia, 
Crigler-Najjar, Hepatitis, Cirrhosis, and hepatocellular carci-
noma. All types of articles (randomized controlled trials, 
clinical observational cohort studies, review articles, case 
reports) were included. Selected references from identified 
articles were searched for further consideration. 
LYSOSOMAL STORAGE DISEASES (LSDs)  
 LSDs are a group of approximately 50 rare inherited 
metabolic disorders that result from defects in lysosomal 
function [46]. Being in most cases of single-gene mutation 
etiology, they present ideal candidates to replacement gene 
therapy, i.e. introducing a wild type gene, the product of 
which substitutes the defective or inadequate enzyme. 
Herein, we examine the prospects of gene therapy in Acute 
intermittent porphyria, Ornithine transcarbamylase, Wilson’s 
disease, Hurler syndrome, Sly syndrome, Pompe disease, 
Tyrosinemia type I, (1)-antitrypsin deficiency, Crigler–
Najjar. Naturally occurring animal homologues of LSDs 
have been described in all common domestic animals, pre-
senting models with critical role in evaluating the efficacy 
and safety of gene therapy (Table 2). 
ACUTE INTERMITTENT PORPHYRIA  
 Acute intermittent porphyria (AIP) is a rare autosomal 
dominant  affecting the biosynthesis of, the oxygen-binding 
prosthetic group of hemoglobin [47] due to a deficiency of 
the enzymehydrogymethylbilane (HMB) synthase, usually 
attributed to a mutation that causes decreased amounts of the 
enzyme, and to a lesser degree by a mutation that causes 
decreased activity. Acute intermittent porphyria is the second 
most common form of porphyria [48]. The acute attacks are 
currently treated with intravenousheme, but a more continu-
ous therapy is needed, particularly for patients experiencing 
frequent attacks [49]. To date, several efforts have been 
made by using non-viral methods, which were unsuccessful, 
as they were incapable of achieving sufficient HMB-
synthase levels due to their poor transfection efficiency in
vivo [50]. In addition, although adenoviral vectors resulted in 
therapeutic HMB-synthase levels in experimental mice, its 
expression was transient, thus making them impractical for 
clinical applications [51].  Administration of recombinant 
adenoviral, AAV8-based andrecombinant AAV (rAAV) vec-
tors in murine models containing the HMB-synthase com-
plementary DNA, resulted in increased levels of hepatic 
HMB-synthase activity, inhibiting the phenobarbital-induced 
ALA and PBG accumulation and thus, indicating a potential 
for future gene therapy[51-53]. Finally, Johansson et al., 
2003 and 2002 showed in mammalian cells that non-viral 
gene delivery encoding HMB-synthase results in high ex-
pression of functional enzyme [54, 55], suggesting enzyme-
replacement gene therapy as a feasible proposal. 
ORNITHINE TRANSCARBAMYLASE DEFICIENCY 
 Ornithine transcarbamylase deficiency (OTCD), the most 
common of the genetic results in an ineffective form of the 
enzyme. Urea cycle defects presenting early in life with hy-
perammonemia remain difficult to treat and commonly ne-
cessitate liver transplantation. Gene therapy has the potential 
to prevent hyperammonemic episodes while awaiting liver 
transplantation, and possibly also to avert the need for trans-
plantation altogether. Ornithinetranscarbamylase (OTC) de-
ficiency provides an ideal model for the development of 
liver-targeted gene therapy.  
 To date, several studies have been performed in OTC-
deficient mouse models (i.e. spfash) using adenoviral and 
more recently rAAV vectors [56-63]. Although a major limi-
tation of this model is the presence of residual OTC enzy-
matic activity, which confers a mild phenotype without clini-
cally significant hyperammonemia. Initial poor results with 
early generation adenoviral vectors [60] have reduced cyto-
toxicity, but have not overcome limitations imposed by con-
siderable intrinsic immunogenicity [62, 63]. In the only 
study reported to date using rAAV, treatment of adult OTC-
deficient mice was investigated using vectors pseudo- sero-
typed with type 7, 8, and 9 capsids [61]. Promising metabolic 
correction was achieved, albeit at high vector doses, and 
declining therapeutic efficacy was observed beyond 250 
days. The type 8 capsid proved most effective although the
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Table 1. Studies for Gene Therapy in Liver Cancer using Viral Vectors
Author Cell line-Animal 
Model 
Viral Vector Transfer gene Combination Overall Application Refs 
Xu et al., 2011 mice onco-
lytic adenovirus 
HCCS1  - improved theurapeutic 178 
Kanai et al., 1997 HuH-7, HLF rAAV CD  - improved theurapeutic 180 
Gan et al., 2008 mice oncolytic adenovi-
rus 
HCCS1 - improved theurapeutic 161 
Wei et al., 2011 HCC cell lines onco-
lytic adenovirus 
SOCS3, TNF - improved theurapeutic 162 
Xue et al., 2010 HepG2, Hep3B, 
MHCC97L, L02 
oncolytic adenovi-
rus 
MDA-7  - improved theurapeutic 163 
Takahashi et al.,
2002
HuH7, HepG2, 
PLC/PRF/5 (P5) 
rAAVs  E1A-13S  - improved theurapeutic 179 
Sagawa et al., 2008 Hep3B Adenovirus p53 - improved theurapeutic 165 
Guo et al., 2001 PLC/PRF/5 
PLC/PRF/5 
rAAV p53  - improved theurapeutic 187 
Chen et al., 2011 Hep3B  rAAV2 p53 DOX improved theurapeutic 182 
Ohashi et al., 2001 mice E1B55k-attenuated 
adenovirus  
E1B  - improved theurapeutic 188 
Wang  et al., 2007 SMMC-7721 mice rAAV  IL-24 - improved theurapeutic 186 
Song et al., 2008 HEK-293 cells rAAVs NT4p53(N15)An  - improved theurapeutic 185 
Xiangji et al., 2011 HepG2.2.15 cells  Lentiviral miR-
based system 
HBsAg - improved theurapeutic 255 
Jin et al., 2011 L-02, WRL-68  oncolytic adenovi-
rus 
let-7 - improved theurapeutic 230 
Xu et al., 2011 HCC cells in G2/M 
phase 
adenovirus MiR-122 ADM or VCR improved theurapeutic 231 
Ma et al., 2010 HepG2, Hep3B, 
Huh7, PLC/PRF/5 
rAAVs miR-122 - improved theurapeutic 243 
Barajas et al., 2001 rats adenovirus IL-12  - improved theurapeutic 206 
Pützer et al., 2001 woodchucks adenovirus IL12/B7.1 - improved theurapeutic 209 
Wei et al., 2011 HCC cell lines oncolytic adenovi-
rus 
SOCS3, TRAIL - improved theurapeutic 162 
Xu et al., 2011 Cancer and normal 
cell lines 
quadruple-regulated 
oncolytic adenovi-
rus 
HCCS1 - improved theurapeutic 178 
Lam et al., 2007 HCC cells HSV-1 chimeric Gal4/NF-
YA
- improved theurapeutic 167 
Argnani et al., 2011 mice HSV-1 luciferase reporter 
gene
- improved theurapeutic 171 
Foka  et al., 2010 HCC cell lines HSV-1 luciferase reporter 
gene
 - Promoter 
ident/tion  
168
Sia et al., 2011 HCC and non-HCC 
cell lines 
HSV-1 luciferase reporter 
gene, (yCD) genes 
yeast yCD -FC5-FC 
prodrug 
improved theurapeutic 170 
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(Table 1) contd…. 
Author Cell line-Animal 
Model 
Viral Vector Transfer gene Combination Overall Application Refs 
Song et al., 2011 HCC cell lines HSV- G207 diploid ICP6  - improved theurapeutic 172 
Wills et al., 1995 HCC cell lines and 
mice 
adenovirus Tk  ganciclovir treat-
ment 
improved theurapeutic 173 
Iwai et al., 2002 mice  EBV-based plas-
mid vector 
HSV-1 Tk  PEI improved theurapeutic 174 
Harada et al., 2000 HCC cells lines  EBV-based plas-
mid vectors 
-gal  EBV/lipoplex-
PAAD 
improved theurapeutic 175 
Chen et al., 2011 HCC cell lines oncolytic adenovi-
rus 
p53  - improved theurapeutic 182 
Inoue et al., 2004 HCC cell lines adenovirus p53  TRAIL-induced 
apoptosis 
improved theurapeutic 183 
Yang et al., 2010 40 Patients adenovirus p53  fractionated stereo-
tactic radiotherapy 
efficient Clinical trial 190 
Tian et al., 2009 1 Patient adenovirus p53  Oxaliplatin, chemo-
therapy and TACE 
efficient Clinical trial 191 
Tian et al., 2009 46 Patients rAAV  p53  TACE efficient pilot phase II 
trial 
192 
Habib et al., 2002 10 Patients E1B-deleted ade-
novirus (dl1520) 
p53  - NSD Clinical trial 189 
Guan  et al., 2005 1 Patient adenovirus p53  TACE efficient Clinical trial 193 
HCCS1; hepatocellular carcinoma suppressor 1, CD; cytosine deaminase gene, SOCS3; suppressor of cytokine signaling 3, TNF; tumor necrosis factor, HSV-Tk; Doxorubicine; 
DOX, herpes simplex virus thymidine kinase gene, IL-24; interleukin-24, HBsAg; surface antigen of hepatitis B virus, IL-12; interleukin-12, MiR; microRNA, TRAIL; tumor necro-
sis factor-related apoptosis-inducing ligand, HSV-1; herpes simplex virus type 1, Adriamycin; ADM,  vincristine ;VCR, TK; thymidine kinase, EBV; epstein barr virus, HSV-1 Tk; 
herpes simplex virus-1 thymidine kinase, polyethylenimine, PEI; EBV/lipoplex; cationic liposome, PAAD; polyamidoamine dendrimer, FC-5; fluorocitosine, TACE; transcatheter 
arterial chemoembolization. 
 
Table 2.  Gene Therapy Published Studies for Metabolic Liver Diseases and Hepatitis 
Author Disease Target Therapeutic 
molecule 
Animal 
Model 
Vector Delivery system Overall Refs 
Johansson et al., 2003 Acute intermit-
tent porphyria  
PBGD  murine Non viral (naked 
DNA) 
intravenous or 
portal vein 
injection 
Not  
improved 
54 
Johansson et al., 2004 Acute intermit-
tent porphyria  
PBGD  mice adenovirus  intravenous NSD 50 
Unzu et al., 2011 Acute intermit-
tent porphyria  
PBGD  mice rAAV  Phenobarbital 
injections 
improved  53 
Johansson et al., 2003 Acute intermit-
tent porphyria  
PBGD   mammalian cells  non-viral intravenous improved  55 
Johansson et al., 2004 Acute intermit-
tent porphyria  
PBGD  mammalian cells  non-viral intravenous improved  51 
Cunningham et al., 2011 Ornithine tran-
scarbamylase  
OTC  mice rAAV  intraperitoneal improved  56 
Kiwaki et al., 1996 Ornithine tran-
scarbamylase  
OTC  mice rAAV intravenous improved  60 
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(Table 2) contd…. 
Author Disease Target Therapeutic 
molecule 
Animal 
Model 
Vector Delivery system Overall Refs 
Mian et al., 2004 Ornithine tran-
scarbamylase  
OTC  mice adenovirus tail-vein injection improved  62 
Brunetti-Pierri et al., 2008 Ornithine tran-
scarbamylase  
OTC  mice adenovirus tail-vein injection improved  63 
Moscioni et al., 2006 Ornithine tran-
scarbamylase  
OTC  mice AAV portal vein  injec-
tion 
improved  61 
Wang et al., 2012 Ornithine tran-
scarbamylase  
OTC  mice AAV8  intravenous  improved  58 
Wang et al., 2011 Ornithine tran-
scarbamylase 
OTC  mice AAV intravenous improved  59 
Roybal et al., 2011 Wilson’s disease ATP7B  murine lentivirus  prenatal improved  68 
Zhang et al., 2011 Wilson’s disease ATP7B Human iPSCs lentivirus  Ex vivo improved 69 
Merle et al., 2006 Wilson’s disease ATP7B  rat lentivirus  systemic applica-
tion 
improved 70 
Ha-Hao et al., 2002 Wilson’s disease ATP7B  rat adenovirus tail-vein injection improved 71 
Liu et al., 2005 Hurler syn-
drome 
IDUA  mice retroviral  intravenous improved 78 
Ma et al., 2007 Hurler syn-
drome 
IDUA  mice retroviral  intravenous improved 80 
Metcalf et al., 2009 Hurler syn-
drome 
IDUA  mice retroviral  intravenous improved 81 
Kobayashi et al., 2005 Hurler syn-
drome 
IDUA  mice lentiviral  intravenous improved 86 
Hartung et al., 2004 Hurler syn-
drome 
IDUA  mice rAAV intravenous improved 85 
Ponder et al., 2006 Hurler syn-
drome 
IDUA  Cats, dogs retroviral intravenous improved 82 
Traas et al., 2007 Hurler syn-
drome 
IDUA Canine dogs retroviral intravenous improved 83 
Herati  et al., 2008 Hurler syn-
drome 
IDUA  dogs retroviral intravenous improved 84 
Di Domenico  et al., 2006 Hurler syn-
drome 
IDUA  mice retroviral intravenous improved 87 
Ma et al., 2007 Hurler syn-
drome 
IDUA  mice retroviral  intravenous improved 80 
Daly et al., 2001 Sly syndrome GUS  mice AAV  intravenous improved 93 
Elliger et al., 2002 Sly syndrome GUS  mice AAV intrathecal, intra-
venous 
improved 94 
Cotugno et al., 2011 Sly syndrome GUS  feline AAV intravascular improved 91 
Ponder et al., 2002 Sly syndrome GUS  dogs retroviral  intravenous improved 96 
Xu et al., 2002 Sly syndrome GUS  mice retroviral intravenous improved 95 
Xu et al., 2002 Sly syndrome GUS  dogs retroviral  intravenous improved 97 
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Author Disease Target Therapeutic 
molecule 
Animal 
Model 
Vector Delivery system Overall Refs 
Sun et al., 2010 Pompe disease GAA  mice AAV retro-orbital 
injection 
improved 101 
Sun et al., 2003 Pompe disease GAA  mice AAV intravenous improved 99 
Sun et al., 2008 Pompe disease GAA  mice AAV intravenous improved 100 
Sun et al., 2010 Pompe disease GAA  mice AAV intravenous improved 101 
Paulk et al., 2010 Tyrosinemia  Fah  mice AAV intravenous facial 
vein 
injection 
improved 103 
Chen et al., 2000 Tyrosinemia Fah  rabbits AAV intravenous improved 104 
Overturf et al., 1996 Tyrosinemia Fah  mice retroviral portal vein injec-
tion 
improved 105 
Overturf et al., 1998 Tyrosinemia Fah  mice retroviral Ex vivo improved 106 
Wilber et al., 2007 Tyrosinemia Fah  murine Non viral (trans-
posase) 
tail-vein injection improved 107 
Montini et al., 2002 Tyrosinemia Fah  mice Non viral (trans-
posase) 
tail vein injection improved 110 
Held et al., 2005 Tyrosinemia Fah  murine Phage phiC31 
integrase  
tail vein injection improved 111 
Overturf  et al., 1997 Tyrosinemia Fah  mice adenovirus Tail or portal vein 
injection 
improved 107 
Grompe 1997 Tyrosinemia Fah  mice retrovirus portal vein injec-
tion 
improved 108 
Yusa et al., 2011 (1)-antitrypsin 
deficiency   
SERPINA1  human iPSCs Non viral (ZFNs) Ex vivo improved 113 
Bortolussi et al., 2011 Crigler-Najjar 
(CNI) syndrome 
hUGT1A1   mice AAV intraperitoneal improved 114 
Birraux  et al., 2009 Crigler-Najjar 
(CNI) syndrome 
hUGT1A1 human cells  lentiviral  Ex vivo improved 115 
Van der Wegen et al., 2006 Crigler-Najjar 
(CNI) syndrome 
hUGT1A1  rat  lentiviral  intravenous improved 116 
Kren  et al., 1999 Crigler-Najjar 
(CNI) syndrome 
hUGT1A1 Gunn rat Non viral (chi-
meric oligonucleo-
tide) 
tail vein injection improved 117 
Morrissey et al., 2005 Hepatitis B virus  HBV  mice Non viral  
(siRNA) 
intravenous improved 127 
Hsu et al., 2003 Hepatitis C virus  serine prote-
ase 
(NS3/NS4A)
Mice (chimeric 
human livers) 
adenovirus infected with 
HCV using the 
serum 
improved 123 
Lang et al., 2011 Hepatitis C 
Virus 
HCV geno-
type 1a/1b
rhesus macaques NS3/NS3A DNA 
Vaccine 
intramuscular 
intramuscular 
improved 129 
Li et al., 2008 Hepatitis B virus  HBV  mice AAV tail vein injection improved 125 
Ebert et al., 2011  Hepatitis B 
virus 
HBV tran-
scripts 
human liver cells 
and mice 
Non viral (siR-
NAs)
Intravenous improved 126 
Zhou et al., 2010 Hepatitis B virus CTLA4-
fused DNA 
mice Non viral (plas-
mid) 
injection at multi-
ple sites 
improved 130 
NSD; not significant difference,  PBGD; porphobilinogen deaminase, AAV; adeno-associated virus, rAAV; recombinant adeno-   associated virus, iPSCs; human induced pluripotent 
stem cells, IDUA; gene responsible for the production of iduronidase enzyme protein production (mapped to the 4p16.3 site on chromosome 4, GUS; beta-glucuronidase reporter 
gene, Fah; furmarylacetoacetate gene, ZFNs; zinc finger nucleases, A1AT or SERPINA1; a(1)-antitrypsin gene, 1A1(hUGT1A1); uridine disphoshate glucuronyltransferase   
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maximal OTC activities achieved were sub-physiological. 
Finally, Cunningham et al., [64] showed that AAV2/8-
mediated transgene delivery is an extremely powerful tool 
for life-long correction of OTC deficiency in the adult 
mouse, but is less robust in neonatal mice, where substantial 
loss of transgene expression occurs during liver growth.  
WILSON’S DISEASE 
 Wilson's disease is a genetic disease caused by mutations 
in the ATP7B gene, which is responsible for the expression 
of a liver transporter protein that coordinates copper export 
into bile and blood [65]. Current medical treatments includ-
ing chelating agents and zinc salts are not effective in all 
Wilson disease patients. Liver transplantation is the alterna-
tive option [65-67]. To date, few gene therapy efforts have 
been tested in animal models of Wilson disease. In the mur-
ine model, adenoviral and lentiviral gene transfer studies 
have shown that viral gene transfer is therapeutically effec-
tive and can reverse clinical symptoms [68-71]. However, 
these approaches were limited by a more or less transient 
transgene expression. Other researchers demonstrated a self-
inactivating lentiviral vector that expresses codon optimized-
ATP7B or treatment with the chaperone drug curcumin 
showing reduction of the functional defect in vitro [69]. In 
conclusion, there is still a long way to go until gene therapy 
can be used for safe treatment of Wilson disease in humans. 
MUCOPOLYSACCHARIDOSES 
 Mucopolysaccharidoses (MPSs) form a group of more 
than 40 caused by the absence or malfunction of enzymes. 
Here we provide information for three of them; MPS I, MPS 
VII and MPS IV concerning results from gene therapy ap-
proaches. 
MPS I  
 Mucopolysaccharidosis type I (MPS IH; Hurler syn-
drome or -L-iduronidase deficiency) is a rare genetic disor-
der caused by mutations in the IDUA gene, resulting the de-
ficiency of -L-iduronidase enzyme activity and intra-
cellular accumulation of glycosaminoglycans (GAGs) [72]. 
The low or absent lysosomal enzyme activity leads to this 
accumulation which is essential to the GAG catabolism, and 
results in systemic impairment of organs and tissues. A char-
acteristic skeletal phenotype is one of the many clinical 
manifestations in Hurler disease. Available treatments for 
patients with MPS I currently consist of hematopoietic stem 
cell transplantation [73] or enzyme replacement therapy [74]. 
Gene therapy as a promising alternative to existing treat-
ments for MPS I, has improved clinical manifestations of the 
disease in a variety of animal models [75]. There are several 
recent reports which designed viral and non-viral vectors for 
Hurler syndrome. For example, Aronovich et al., [76, 77] 
demonstrated the reversion of MPS I phenotypein adult 
mice, using therapeutic SB transposon plasmids encoding 
human IDUA.
However, most of the approaches include viral vectors.  In 
particular, neonatal administration of -retroviral vectors (-
RV) [78-81], lentiviral vectors, or AAV vectors expressing 
the IDUA gene have prevented many aspects of MPS I dis-
ease in mice, while -RV have been effective in dogs and 
cats [82-85]. Administration of a -RV7 or a lentiviral vector 
[86, 87] to adult mice without immunosuppression, had no 
therapeutic effect. Ma et al., [80] showed improvement in 
MPSI symtopatology in adult mice, after retroviral vector-
mediated gene therapy with immunomodulation. 
MPS VI 
 Mucopolysaccharidosis type VI (MPS-VI) is an autoso-
mal recessive lysosomal storage disorder caused by the defi-
ciency of N-acetylgalactosamine-4-sulfatase (4S; or ARSB). 
Mutations in the 4S gene are responsible for 4S deficiency, 
which leads to the intralysosomal storage of partially de-
graded glycosaminoglycans, dermatan sulfate, and chon-
droitin 4-sulfate [88]. The disorder shows a wide spectrum of 
symptoms from slowly to rapidly progressing forms. The 
characteristic skeletal dysplasia includes short stature, 
dysostosis multiplex and degenerative joint disease. Moreo-
ver, before enzyme replacement therapy (ERT) with galsul-
fase (Naglazyme), clinical management was limited to sup-
portive care and hematopoietic stem cell transplantation. 
Galsulfase is now widely available and is a specific therapy 
providing improved endurance with an acceptable safety 
profile.  
 Few reports have demonstrated the utility of viral vectors 
in MPS VI. Byers et al., [89], indicated that the lentiviral 
vector can be used to deliver 4S to a range of joint tissues in
vitro and efficiently transduce synovial cells to express beta-
galactosidase in vivo. A study by Ho et al., [90], supported 
the utility of AAV as a vector for the treatment of retinal 
pigment epithelium (RPE) cells of feline MPS VI. Finally, 
Cotugno et al., [91] showed that intravascular administration 
of AAV in MPS VI cats, represents a promising therapeutic 
strategy for MPS VI patients. 
SLY SYNDROME  
 Another example of treating LSDs with gene therapy is 
MPS type VII or Sly syndrome. Here, the gene of interest 
encodes -glucuronidase (GUS), whose absence or func-
tional defectiveness causes a buildup of glycosaminoglycan 
(GAG) storage granules within the lysosomes of most cell 
types [92]. In humans, this disease is characterized by mental 
retardation, abnormal bone development, distorted features, 
and organ malfunctions leading to organ failure and early 
death. Fortunately, Sly syndrome is rare; however, because a 
great deal is known about GUS and because there are animal 
models of this disease, Sly syndrome has become a paradigm 
for the study of lysosomal storage diseases in general and for 
gene therapy in particular. Furthermore, complete regulation 
of expression is not necessary, as has been found that over-
expression does not cause problems, and if 2% of normal 
levels are restored the abnormal phenotype is reversed. 
These features make this disease an ideal target for the appli-
cation of gene technology. 
 Attempts for gene therapy in MPS VII in animal models 
involve intravenous injection of vectors derived from AAV, 
adenovirus, retrovirus or a plasmid. Daly et al., [93] reported 
that AAV-mediated gene transfer in the neonatal period can 
lead to the prevention of many of the clinical symptoms as-
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sociated with MPS VII in the murine model. Indeed, thera-
peutic levels of enzyme persist for at least 1 year following a 
single intravenous injection of virus in neonatal MPS VII 
mice. The level and distribution of GUSB expression were 
sufficient to prevent many clinical symptoms over the life of 
the animal. By adding coding sequences for secretion (Ig)
and uptake (HIV-1 TAT) signals to the GUS gene delivered 
by AAV, and treated mice both intrathecally and intrave-
nously as newborns, Elliger et al., [94] have increased the 
GUS enzyme levels in more tissues and have improved the 
health of the mice so much that they were able to breed [94]. 
Several more recent reports attempted gene therapy for MPS 
VII in animal models; one approach involves neonatal i.v. 
injection of a -retroviral vector expressing -glucuronidase, 
which results in transduction of liver cells and secretion of 
enzyme into blood in significant levels [95-97]. In conclu-
sion, gene therapy holds great promise for providing a long-
lasting therapeutic effect for MPS VII if safety and higher 
expression levels issues can be resolved [75]. 
POMPE DISEASE 
 The Glycogen storage disease type II (GSD II) is another 
LSD, also known as acid maltase deficiency or Pompe dis-
ease. It is caused by mutations in the gene of acid alpha-
glucosidase (GAA), the enzyme responsible for breaking 
down glycogen into glucose, causing absence or significantly 
reduction in enzyme levels. Classic infantile-onset Pompe 
disease may be apparent in utero but it more often presents 
in the first month of life with hypotonia, generalized muscle 
weakness, cardiomegaly and hypertrophic cardiomyopathy, 
feeding difficulties, failure to thrive, respiratory distress, and 
hearing loss. The existing available treatment reverses car-
diac muscle damage and enhances life expectancy in those 
with the infantile form of the disease, but is less effective in 
skeletal muscle. 
 Some recent approaches include gene therapy by using 
viral vectors. Koeberl et al., [98] reported that immune toler-
ance to the transgene could be achieved by liver-specific 
expression with AAV vectors by enhancing the efficacy. Sun 
et al., [99-101] made several efforts in murine Pompe dis-
ease by administrating AVV vectors with promising results. 
Despite the presence of immune responses, the successful 
development of gene therapy in mice is a fact, which indi-
cates that curative therapy for Pompe disease may become 
available in the foreseeable future. 
TYROSINEMIA 
 Tyrosinemia is caused by a shortage of enzyme fumary-
lacetoacetate hydrolase (FAH) [102]. The usual manifesta-
tions appear in the first few months of life and include failure 
to gain weight and grow at the expected rate (failure to 
thrive), diarrhea, vomiting, yellowing of the skin and whites 
of the eyes (jaundice), cabbage-like odor, and increased ten-
dency to bleed (particularly nosebleeds). Tyrosinemia can 
lead to liver and kidney failure, problems affecting the nerv-
ous system, and an increased risk of liver cancer. Toxic me-
tabolites such as fumarylacetoacetate accumulate in hepato-
cytes and renal proximal tubules, causing death in a cell-
autonomous manner [102]. 
 Paulk et al., [103] demonstrated stable hepatic gene re-
pair in both adult and neonatal mice with AAV-FAH sero-
types 2 and 8, showing that AAV-mediated gene repair is 
feasible in vivo and can functionally correct enzyme-
deficiency consequences. In a study by Chen et al., [104] a 
murine model for hereditary tyrosinemia was used to evalu-
ate in vivo gene therapy with AAV vectors expressing FAH. 
Results reported that after 9 months, vector-treated animals 
showed benign hepatomas, whereas in untreated animals 
areas of marked dysplasia were present within hepatomas. 
Furthermore, Overturf et al., [105, 106] demonstrated in vivo
and ex vivo successful effects in murine models by adminis-
trating adenoviral vector [107] but in therapeutic trials, 
Grompe et al., showed that 2/3 treated animals developed 
hepatocarcinoma after 1 year retroviral gene transfer [108].  
Wilber et al., [109] tested the use of transposase-encoding 
RNA plus transposon DNA for correction of murine FAH 
deficiency. The authors concluded that transposase-encoding 
messenger RNA (mRNA) can be used to mediate stable non-
viral gene therapy, resulting in complete phenotypic correc-
tion. Using the same strategy, Montini et al., [110] demon-
strated long-lasting correction of the FAH-deficiency pheno-
type. 
 Finally, Held et al., [111] used Phage phiC31 integrase, 
which is a site-specific recombinase that mediates efficient 
integration of circular extra-chromosomal DNA into the host 
genome. They used this integrase system to transfer the FAH 
gene into the liver of mice affected with hereditary tyrosine-
mia, suggesting that it may have utility in many gene therapy 
settings. Overall, several gene therapy strategies have shown 
therapeutic potential for tyrosinemia, which still needs to be 
proven in humans.  
(1)-ANTITRYPSIN DEFICIENCY   
 Alpha 1-antitrypsin deficiency (1-antitrypsin deficiency, 
A1AD or simply Alpha-1) is a recessive caused by defective 
production of  (A1AT also known as SERPINA1). This miss 
expression leads to decreased A1AT activity in lungs, and 
deposition of excessive abnormal A1AT protein in liver cells 
[112]. The enzyme deficiency causes pulmonary emphy-
sema, while 10% of patients develop cirrhosis due to accu-
mulation of defective folded protein. The administration of 
the enzyme gene with adenovirus could reverse the lung 
damage in mice and baboons, while for liver cirrhosis gene 
repair is essential.  
 Yusa et al., [113] showed that a combination of zinc fin-
ger nucleases (ZFNs) and piggyBac technology in human 
induced pluripotent stem cells and achieved biallelic correc-
tion of a point mutation (Glu342Lys) in the A1AT. Genetic 
correction of human induced pluripotent stem cells restored 
the structure and function of A1AT in subsequently derived 
liver cells in vitro and in vivo. This approach is significantly 
more efficient than any other gene-targeting technology that 
is currently available and prevents contamination of the host 
genome with residual non-human sequences. 
CRIGLER–NAJJAR 
 Crigler–Najjar syndrome is characterized by unconju-
gated hyperbilirubinemia resulting from an autosomal reces-
sive inherited deficiency of hepatic UDP-glucuronosyl-
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transferase (UGT) 1A1 activity. The enzyme is essential for 
glucuronidation and biliary excretion of bilirubin, and its 
absence can be fatal. Bortolussi et al., [114] by using AAV9-
mediated gene transfer, showed the rescue of bilirubin-
induced neonatal lethality in a mouse model of Crigler-
Najjar syndrome. In addition, Birraux et al., [115] and 
Wegen et al., [116] showed successful treatment of Crigler-
Najjar syndrome, by administrating the human UGT1A1 with 
lentiviral vectors in mice and rat animal models respectively. 
Kren et al., [117] showed permanent correction of the 
UGT1A1 genetic defect in Gunn rat liver with site-specific 
replacement of the absent G residue at nucleotide 1206 by 
using an RNA/DNA oligonucleotide designed to promote 
endogenous repair of genomic DNA. However, none of these 
protocols have so far been translated into a clinical trial 
[118]. 
HEPATITIS C AND B 
 Hepatitis C virus (HCV) infection is a serious global 
health problem that affects 180 million people worldwide 
[119]. Hepatitis C virus is a major cause of chronic liver dis-
eases which can lead to permanent liver damage, hepatocel-
lular carcinoma and death [120]. The present available 
treatment with interferon plus ribavirin, has limited benefits 
due to adverse side effects such as anemia, depression and 
“flu-like” symptoms. Hence, the development of a new 
treatment is crucial, and gene therapy is on target. In this 
case, the goal of treatment is to resolve the viral potential for 
infection, cirrhosis and liver failure and not develop liver 
cancer. 
 An option for HCV eradication is RNA which  is an at-
tractive target for RNAi, as the single positive-stranded viral 
transcript functions both as genomic RNA and a replication 
template, and also because of its localization in the infected 
liver, an organ that can be readily targeted by nucleic acid 
molecules and viral vectors. Several reports demonstrated 
potent RNAi activity against HCV in sub-genomic replicon 
and fully infectious HCV particles [121]. A review of Ash-
faq et al., [122] concluded that combination of siRNA 
against virus and host genes will be a better option to treat 
HCV. 
 Alternatively, suicide gene therapy is based on admini-
stration of genes encoding cytotoxic agents that have been 
modified to be expressed only in cells infected by the virus 
of hepatitis. For example, a chimeric molecule that when cut 
by a protease of HCV releases BID, an agent that induces 
apoptosis in infected cells. Another report demonstrated that 
modified apoptotic molecule (BID) reduces hepatitis C virus 
infection in mice with chimeric human livers [123]. 
 Hepatitis B is also an infectious illness caused by (HBV) 
which infects the liver of hominoidea, including humans, and 
causes hepatitis [124]. Interferon-alpha2 (IFNalpha2) is rou-
tinely used for anti-hepatitis B virus (HBV) treatment. How-
ever, as in HCV, the therapeutic efficiency is unsatisfactory 
too. Liz et al., [125] managed to decrease the level of viral 
DNA over 30-fold for several weeks by testing a single dose 
of vector-delivered IFNalpha1 for its anti-HBV effects. An-
other recent report combined gene silencing by using 5' 
Triphosphorylated siRNAs control replication of hepatitis B 
virus with induction of IFN in the liver [126]. As in HCV, 
there is also a report demostrating that siRNA may be a 
clinically viable therapeutic approach for HBV [127].    
 An alternative therapeutic approach that combines gene 
silencing with induction of IFN in the liver was demon-
strated by Ebert et al., [126]. He reported that this combina-
tion in HBV-infected primary human hepatocytes and in 
HBV transgenic mice controlled replication of HBV effi-
ciently. In general, it is well-recognized that a combination 
of gene therapy antiviral treatment and immunomodulation is 
essential to achieve a sustained control of HBV and HCV 
infection.
 Another way for activation anti-viral immunity, which 
may have therapeutic and preventive clinical value, is DNA-
vaccines that induce the synthesis of viral antigens of hepati-
tis B or C - surface and central. There are plenty of advan-
tages for such a vaccine; the easy production and storage - 
since the DNA is much more stable than the respective pro-
tein antigens, the potential for epidermal (particle-mediated 
epidermal delivery, PMED), the reduction of contamination, 
the possibility of parallel immunization with different genes, 
and the use of DNA induces cytotoxic immune response. 
This response is induced because the antigen is expressed 
intracellularly just as in cells infected with actual virus and 
thus immunity is more effective and more permanent. Clini-
cal trials of DNA vaccines given intramuscularly, or trans-
dermal method of gene-gun-show absence of toxicity and 
development of effective immunity [128]. The parallel ad-
ministration of interferon genes has also been suggested as a 
treatment regimen. Numerous studies have suggested that an 
effective hepatitis C virus (HCV) vaccine must induce a 
strong T helper 1 (Th1) T cell response. Lang et al., [129]
used the rhesus macaque vaccination model in assessing 
HCV DNA vaccine-induced T cell responses and presented a 
useful tool in the evaluation of immune responses induced by 
HCV immunogens. Finally, the increased immunogenicity of 
DNA vaccines can be achieved by the fusion of specific an-
tigens to extracellular domain of cytotoxic-T-lymphocyte-
associated antigen 4 (CTLA4) which represents a promising 
approach. Zhou et al., [130] evaluated this interesting ap-
proach for its enhancement on HBV-specific immune re-
sponses and its antiviral effects in HBV transgenic mice. 
Thus, the CTLA4-fused DNA vaccine led to breakdown of 
immune tolerance to viral infection in HBV transgenic mice, 
which might be used as a therapeutic vaccine in HBV infec-
tion. 
LIVER CIRRHOSIS 
 Liver cirrhosis is the irreversible end result of fibrous 
scarring and hepatocellular regeneration, characterized by 
diffuse disorganization of the normal hepatic structure of 
regenerative nodules and fibrotic tissue. It is associated with 
prominent morbidity and mortality, and is induced by many 
factors, including chronic hepatitis virus infections, alcohol 
drinking and drug abuse. The treatment aims at limiting he-
patocyte destruction and decreasing fibrosis. Hepatocyte 
growth factor (HGF), originally identified and cloned as a 
potent mitogen for hepatocytes, shows mitogenic, motogenic 
and morphogenic activities for a wide variety of cells. 
Moreover, HGF plays an essential part in the development 
and regeneration of the liver, and shows anti-apoptotic activ-
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ity in hepatocytes. In a rat model of lethal liver cirrhosis pro-
duced by dimethylnitrosamine administration, repeated 
transfections of the human HGF gene into skeletal muscles 
induced a high plasma level of human as well as enodoge-
nous rat HGF, and tyrosine phosphorylation of the c-
Met/HGF receptor. Transduction with the HGF gene also 
suppressed the increase of transforming growth factor-beta1 
(TGF-1), which plays an essential part in the progression of 
liver cirrhosis, inhibited fibrogenesis and hepatocyte apopto-
sis, and produced the complete resolution of fibrosis in the 
cirrhotic liver, thereby improving the survival rate of rats 
with this severe illness. Thus, HGF gene therapy may be 
potentially useful for the treatment of patients with liver cir-
rhosis, which is otherwise fatal and untreatable by conven-
tional therapy [131].  
 TGF-1 and its signaling pathway also present targets for 
gene therapy. One approach is to deliver dominant negative 
gene for defective receptor in order to dimerize with the wild 
type receptor and inactivate it, or alternatively hyper-
expression of Smad7, a signal transduction element that an-
tagonizes secondary TGF-1 messengers. The inhibition of 
TGF-1 has been demonstrated by several authors either by 
using adenoviral vectors [132-135], recombinant plasmid 
[136] or siRNA [137] in vivo, resulting in the prevention of 
liver fibrosis. The second approach which includes the hy-
per-expression of Smad7, totally blocks TGF-1 signal 
transduction.  Indeed, several studies demonstrated that ade-
novirus-mediated overexpression of Smad7 in rats [138-141] 
resulted in significant inhibition of fibrosis. Besides, TGF-1
is also a key mediator of liver fibrosis [142-144]. Arias et al., 
[145, 146] demonstrated that adenoviral expression of a 
TGF-1 antisense mRNA is effective in preventing liver 
fibrosis in bile-duct ligated rats. Furthermore, Yeom et al., 
[147] constructed a siRNA targeting Smad3 which prevented 
the activity of TGF-1. 
 In conclusion, gene therapy may be potentially useful for 
the treatment of patients with liver cirrhosis, which however 
remains to be proven in human. 
LIVER CANCER 
 Liver cancer is one of the most common malignant tu-
mors worldwide and the third leading cause of cancer-related 
death. Because of its high malignancy and fast progression, 
most high-grade patients have tumors that are unresectable. 
Plenty of pathways are involved in the development of hepa-
tocellular carcinoma (HCC) and are depicted as follows: (a) 
activation of the Wnt/Frizzled/catenin pathway through mu-
tations in catenin as well as up-regulation of upstream ele-
ments, such as Frizzled receptor, (b) alteration of the MAPK 
signaling pathway through HBV or HCV infection, (c) acti-
vation of the JAK/STAT pathway through inactivation of 
JAK-binding proteins, (d) inactivation of the tumor suppres-
sor gene p53 through gene mutation and posttranscriptional 
interaction with viral proteins as well as oxidative stress, (e) 
alteration of the tumor suppressor retinoblastoma (pRb 
pathway) and p16INK4 genes through mutations or promoter 
methylation, and (f) alteration of the TGF- pathway [148]. 
Furthermore, many HCC-related oncogenes, including 
AFP,RAS, c-FOS, c-JUN, RHO, TGF-a, HGF, CerbB2, 
HER-2,HER-2/neu, NEU, NGL, MDM2, MMP, and IGF,
have been found. The abnormal expression of these genes 
with regard to uncontrolled cell proliferation results ulti-
mately in carcinogenesis [149]. 
 The best curative options for the treatment of liver cancer 
are the surgical resection and liver transplantation. Chemo-
therapy and radiotherapy are also applied, however with ma-
jor drawbacks such as the high frequency of tumor recur-
rence, metastasis and generally low responses. Moreover, 
recent experimental treatment approaches, including hormo-
nal therapy, biologic, biochemical therapy [150-154], and 
molecular targeted therapy [155-158], are still needed to be 
verified in clinical application. Thus, there is an urgent need 
to develop novel treatments for recurrent and advanced 
HCC. Gene therapy suggests a novel and promising ap-
proach for liver cancer via a variety of gene transfer strate-
gies aiming to the treatment of patients with primary and 
secondary liver tumors, including gene directed enzyme/pro-
drug therapy, inhibition of oncogenes and restoration of tu-
mor-suppressor genes, immunotherapy, anti-angiogenesis 
and virotherapy (Fig. 1). Some of these strategies have 
reached early clinical development with diverting success.
INHIBITION OF ONCOGENES AND RESTORATION 
OF TUMOR-SUPPRESSOR GENES BY ONCOLYTIC 
AND OTHER VIRUSES 
 The strategy of “Cancer Targeting Gene-Viro-Therapy” 
(CTGVT) was developed in 2001 [159] and has increased 
expectations in the treatment of cancer. It combines the ad-
vantages of gene therapy and oncolytic viral therapy. Onco-
lytic adenoviruses can replicate themselves in cancer cells 
and lyse the carcinoma, whereas they are very inefficient in 
normal cells. Tumor suppressor genes can replicate together 
with oncolytic viral vectors, thereby greatly enhancing the 
ability to induce cancer cell death [160]. In published stud-
ies, oncolytic adenovirus-mediated gene therapy has pro-
duced good results in targeting cancer cells. However, safety 
and efficacy, the two most important aspects in cancer ther-
apy, remain serious challenges. 
 Gan et al., [161] inserted the novel tumor suppressor 
gene hepatocellular carcinoma suppressor 1 (HCCS1) into 
an oncolytic adenovirus and exhibited a dramatic inhibitory 
effect on cancer cells in vitro and in vivo,  leading to a com-
plete regression of 50% of established tumor xenografts in 
nude mice. However, the antitumor efficacy of oncolytic 
adenoviruses on human hepatocellular carcinoma (HCC) 
cells was compromised due to low expression of the adeno-
virus serotype 5 (Ad5) receptor on the target cells. 
 Wei et al., [162] incorporated two therapeutic genes, 
suppressor of cytokine signaling 3 (SOCS3) and tumor ne-
crosis factor-related apoptosis-inducing ligand (TRAIL) into 
a double-regulated oncolytic adenovirus vector. Their results 
exhibited potent antitumor activity in carcinoplacental anti-
gen -fetoprotein (AFP)-positive HCC cell lines both in vitro
and in vivo. Another report also tested the oncolytic adenovi-
rus vector, enhancing the antitumor activity in HCC cell 
lines with similar results [163].  
 Moreover, to specifically target liver malignant cells, 
cancer gene therapy needs to combine highly selective gene 
delivery with highly specific gene expression. Towards this 
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target, several approaches have been made [164-169]. Her-
pes virus simplex type-1 (HSV-1) is one of the most promis-
ing viral platforms for transferring therapeutic genes and the 
development of oncolytic vectors that can target, multiply in, 
and eradicate hepatoma cells via their lytic cycle. More spe-
cifically, Foka et al., [168] identified and experimentally 
characterized novel hepatoma-specific promoters, which 
were valuable for cancer-specific gene therapy, by using 
HSV-1 vectors. Sia et al., [170] used as a viral vector the 
HSV-1 amplicon in HCC and non-HCC cell lines in vitro
and in vivo with promising results. Several other reports 
characterized different kinds of HSV-1 vectors as platforms 
for virotherapy against liver cancer [167, 168, 171-173].  
 Researchers have also used Epstein-Barr virus (EBV)-
based plasmid vectors and demonstrated suicide gene ther-
apy in vitro and in vivo suggesting efficient expression of the 
gene [174-176]. More specifically, these reports demon-
strated in mice and in HCC cells that (EBV)-based plasmid 
vectors coupled with polyamidoamine dendrimer or polyeth-
ylenimine-mediated is a very useful tool in suicide gene 
therapy of cancer.  
 The gene of the carcinoplacental antigen -fetoprotein 
(AFP) is overexpressed in HCC which makes it also a target 
of gene therapy. Kanai et al., [177] demonstrated that repli-
cation defective recombinant adenoviral vectors, containing 
the human AFP promoter/enhancer, can be used to express 
the Escherichia coli cytosine deaminase (CD) gene 
(AdAFPCD) and the -galactosidase gene (AdAF-PlacZ) in 
AFP-producing HCC cell lines. Hai-Neng Xu et al., [178]
showed reduced toxicity and excellent anti-liver cancer effi-
cacy by using quadruple-regulated adenoviruses carrying an 
AFP promoter-controlled HCCS1 gene both in vitro and in
vivo. Other reports also used adenoviral vectors for AFP de-
livery in hepatocellular carcinoma cells in vitro  or in vivo in 
animal models showing promising strategies for cancer spe-
cific therapy which may have clinical use in the future  [179, 
180]. 
 Abnormalities of p53 are also considered a predisposition 
factor for hepatocarcinogenesis as p53 is frequently mutated 
in HCC [181]. p53 gene transfer has been proposed as a po-
tential therapeutic option for treatment of HCC. Some re-
searchers used adenoviral-mediated transfer or oncolytic 
adenovirus by expressing p53 fiber chimeric oncolytic ade-
novirus in combination with p53 expression, promising a 
safe anticancer agent for the treatment of HCC [182, 183]. 
Furthermore, Gu et al., [184] studied the effect of adenovirus 
(Ad)-p53 gene therapy on HCC in a rabbit model and con-
cluded that trans-arterial Ad-p53 gene therapy can reduce 
tumor growth of HCC. In a series of published studies data 
were presented of a constructed recombinant adenovirus 
vectors by replacing E1 region by exogenous DNA, demon-
strating induction of HCC cell cytotoxicity and apoptosis in
vitro and in vivo [185-188]. Habib et al., [189] attempted a 
clinical trial of E1B-deleted adenovirus (dl1520) gene ther-
apy for HCC with no effective antitumor results. This study 
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showed that the adenovirus was well tolerated, but did not 
seem to offer significant tumor control. Several clinical stud-
ies of (Ad)-p53 combined with fractionated stereotactic ra-
diotherapy or with chemotherapy and trans-catheter arterial 
chemo-embolization for HCC were conducted and presented 
promising results [190-193]. Recombinant adenoviral vector 
expressing wt-p53 (Ad-p53) [209] yield a relatively low de-
gree of acute toxicity, compared to other commonly used 
gene transfer vectors such as adenovirus and retrovirus, re-
combinant AAV serotype 2 (rAAV2) [214] has shown prom-
ising results in human clinical trials. Significant enhance-
ment in the gene transfer efficiency is needed, however, for 
HCC applications. 
IMMUNOTHERAPY 
 Cancer immunotherapy can be defined as the techniques 
used to eliminate malignant tumors through mechanisms 
through immune system responses [194, 195]. The goal of 
cancer immunotherapy is to direct against tumors extremely 
potent immune responses such as those naturally occurring 
against microbial antigens, and subsequently apply these 
results to human cancer diseases [196]. Cancer represents 
almost 70% of the clinical trials conducted in patients and 
25% of these studies consisted in the application of cytokine 
genes [196]. Two main approaches have been used in gene 
transfer of immunostimulatory cytokines (e.g. IL-2, IL-4, IL-
6, IL-7; IL-12, INF-, TNF-, GM-CSF) [144]: i) vectors 
expressing cytokines/chemokines/costimulatory molecules 
injected directly into tumor lesions, or ii) transduction of 
tumor /dendritic cells ex vivo with vectors expressing cytoki-
nes/costimulatory molecules [196]. Several reports demon-
strated the potential usefulness of IL-12 gene transfer for 
liver tumors treatment in animal models, mostly by using 
adenovirus vectors [197-211]. Recent studies showed that 
the combination of cytokines with anti-angiogenic gene 
therapies achieved better antitumor effects on large tumors 
[162]. 
 The other immunotherapy strategy includes the use of 
oncolytic viruses for cytokine gene delivery which also of-
fers a promising treatment of liver tumors [189, 212-215]. As 
discussed earlier, these vectors are considered quite effec-
tive, associated with higher infectious rate and prolonged 
expression. However, gene therapy with oncolytic viruses in 
hepatoceccular carcinoma induced also immune responses, 
expression of heterologous genes in unwanted tissues or cells 
that could shut down the function gene expression [216].  
microRNA  
 One of the most promising anticancer therapies involves 
the use of microRNA (miRNA), the efficacy of which 
mainly depends on the efficiency of the delivery system 
[217, 218]. miRNAs are a class of short endogenous RNAs. 
There are about 1000 known miRNA today. A lot of findings 
suggest the involvement of miRNAs in the pathogenesis of 
HCC, i.e. the irregular expression of miRNAs [219-227] and 
the association with the clinical outcome of cancer patients 
[228, 229]. miRNAs may function as oncogenes while others 
act as tumor suppressors; studies in animal models treated 
with miRNAs or in combination with chemotherapy showed 
promising results [230-251] (Table 3).  The identification of 
miRNA function involved in liver cancer has provided an 
important knowledge regarding miRNA tumor associated 
gene interactions and revealed many potential therapeutic 
targets.  
CONTROL OF TUMOR MICROENVIRONMENT 
 The microenvironment of the HCC is composed of non-
tumor cells and their stroma, with the stroma having been 
implicated in the regulation of tumor growth, metastatic po-
tential and outcome following therapy. Niess et al., [252]
used engineered mesenchymal stem cells (MSCs) as thera-
peutic vehicles for the treatment of HCC. They concluded 
that stem cell-mediated introduction of suicide genes into the 
tumor followed by pro-drug administration was effective 
towards liver cancer [252].  
ACUTE LIVER FAILURE  
 Acute liver failure (ALF) is a life-threatening medical 
emergency and occurs when the liver rapidly looses its func-
tion within a short period. ALF is mainly caused by viral 
infections, primarily HBV (hepatitis B virus), HAV (hepati-
tis A virus) and HEV (hepatitis E virus) in the East and de-
veloping countries, such as China and India [253, 254]. In 
contrast, the majority of ALF is resulted from a drug over-
dose in the West and developed countries. ALF can also be 
developed secondarily due to a variety of causes such as in-
fection with non-hepatotropic viruses, including cytomega-
lovirus, Epstein-Barr virus, adenovirus and hemorrhagic fe-
ver virus, vascular diseases, such as Budd-Chiari syndrome 
and venoocclusive disease, metabolic diseases, such as Wil-
son’s syndrome, Reye’s syndrome, acute fatty liver of preg-
nancy and galactosemia, and idiosyncratic drug/toxin reac-
tions [255]. Currently, the orthotopic liver transplantation 
(OLT) is the "Gold Standard" therapy for the disease. How-
ever, due to the limited availability of donor organs and rapid 
progression of the disease, the mortality of ALF remains 
high. Therefore, it is imperative to develop novel therapeutic 
reagents for ALF. Gene therapy by delivering a target gene 
to the patients appears to be a promising approach for the 
treatment of ALF. Besides, the asialoglycoprotein receptor 
(ASGP-R) is uniquely and highly expressed on hepatocytes, 
offering a mechanism for glycoprotein-mediated hepatocyte-
specific delivery [256]. In contrast, the major drawback for 
ALF gene therapy is that multiple factors contribute for its 
development, such as apoptosis, necrosis, inflammation and 
liver regeneration. 
 Therefore, gene therapy for treating ALF is still in its 
infancy. Several studies report successful development of 
gene therapy for ALF in animals, mostly mice [257-267]. 
The main non viral vectors used in theses references are 
siRNA antisense oligonucleotides and Zinc-finger nucleases 
(ZFNs). Currently, there is no large-scale clinical trial to test 
a specific gene. However, gene therapy holds great promise 
in inhibition of the disease progression, benefiting the ALF 
patients. Potentially, gene therapy may become an alternative 
or at least complement to OLT for intervention of ALF pa-
tients. Zhu et al., [268] proposed targeting fgl2 for inhibiting 
necrosis, together with Fas to reduce apoptosis and HGF to 
promote liver regeneration; this multitarget approach could 
synergistically block the progression of ALF. 
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Table 3. MicroRNA (miR) for Hepatocellular Carcinoma (HCC) 
Author Cell line-Animal model-clinical trial Non-viral vector- miR Overall Refs 
Fang et al., 2011 mice miR-29b improved 232 
Xu et al., 2011 HCC cells in G2/M phase miR-122 improved 231 
Yang et al., 2011 HCC cells miR-122 improved  233 
Li et al., 2011 mice miR-99a improved 221 
Zhou et al., 2011 HCC cells miR-1274a improved 235 
Young et al., 2010 HCC cells miR-122 improved 239 
Fornari et al., 2010 HCC cells miR-199a-3p improved 240 
Shimizu et al., 2010 Huh7 and HepG2 cell lines, primary 
human hepatocytes 
miR let-7  improved 241 
Liu et al., 2010 non-tumor tissues of HCC patients miR-375 improved 242 
Ma et al., 2010 Cancer cells 
HepG2, Hep3B, Huh7 and PLC/PRF/5 
miR-122 improved 243 
Xu et al., 2009 HCC patients miR-195 improved 246 
Suzuki et al., 2008 HCC miR-122a improved 248 
CONCLUSIONS 
 In this review, we have focused on the ongoing develop-
ment of gene therapy in liver diseases. We summarized the 
different strategies that have been explored to improve the 
efficacy of gene therapy in these diseases. During the past 
decade, gene therapy has offered plenty of therapeutic op-
tions. Unfortunately, a clear therapeutic effect for most of the 
liver diseases has not yet been achieved. Several reasons 
could explain these results; the neutralization of the virus by 
the immune system, severe toxicity, and low levels of target-
specific gene delivery. Despite several efforts in clinical re-
search trials the effectiveness and clinical utility were un-
dermined also by several limitations, such as insufficient 
delivery, intravascular administration and short-lived trans-
gene expression. Still, gene therapy for liver cancer is mov-
ing towards clinical application with promising results and 
especially when the virus is administered in combination 
with existing chemotherapy and radiation therapy. Hope-
fully, the ever growing knowledge on molecular pathways 
and the construction of improved and more effective vectors 
will shed new light on the right path in order to ensure the 
best clinical efficacy. 
 Nonviral vectors are simpler, safer, and less expensive 
than viruses and offer very large carrying capacities. Trans-
fection efficiency can be increased by associating the DNA 
with a carrier, such as a liposome or a polymer, or through 
the use of a physical stimulus, such as an electric pulse (elec-
troporation). Nonviral gene delivery (transfection) remains 
much less efficient than viral gene delivery (transduction) 
and this remains a barrier to its wider use. Recent progress in 
vector technology and imaging techniques, allowing in vivo
assessment of gene expression, will facilitate the develop-
ment of clinical applications of gene therapy. Although only 
a small number of patients were treated, it becomes apparent 
that more effective vectors are needed to achieve a useful 
clinical impact. Overall, the numerous experimental strate-
gies addressing gene therapy efficacy in liver diseases need 
to be evaluated in clinical trials and may offer successful 
therapeutic alternatives.   
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